טוען...
Cutaneous adverse events in multiple sclerosis patients treated with daclizumab
OBJECTIVE: To analyze the spectrum and mechanisms of cutaneous adverse events (AEs) in patients with multiple sclerosis treated with daclizumab high-yield process (DAC-HYP). METHODS: A total of 31 participants in an institutional review board–approved open-label phase I study of DAC-HYP (NCT01143441...
שמור ב:
| הוצא לאור ב: | Neurology |
|---|---|
| Main Authors: | , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Lippincott Williams & Wilkins
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4793779/ https://ncbi.nlm.nih.gov/pubmed/26843560 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0000000000002417 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|